AstraZeneca PLC (AZN)

pos +0.00
Today's Range: 30.61 - 30.86 | AZN Avg Daily Volume: 5,387,800
Last Update: 10/21/16 - 4:03 PM EDT
Volume: 0
YTD Performance: -9.51%
Open: $0.00
Previous Close: $31.00
52 Week Range: $26.97 - $35.04
Oustanding Shares: 2,530,000,000
Market Cap: 78,430,000,000
6-Month Chart
TheStreet Ratings Grade for AZN
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 2 2 1 1
Moderate Buy 0 0 0 0
Hold 2 2 3 3
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 2.00 2.00 2.50 2.50
Latest Dividend: 0.44
Latest Dividend Yield: 4.42%
Dividend Ex-Date: 08/10/16
Price Earnings Ratio: 13.90
Price Earnings Comparisons:
AZN Sector Avg. S&P 500
13.90 35.50 29.40
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
0.62% 0.82% 19.72%
Revenue -5.30 -0.10 -0.04
Net Income 128.80 -0.60 -0.23
EPS 127.60 -0.60 -0.23
Earnings for AZN:
Revenue 24.71B
Average Earnings Estimates
Qtr (09/16) Qtr (12/16) FY (12/16) FY (12/17)
Average Estimate $0.48 $0.60 $2.02 $1.91
Number of Analysts 3 1 2 3
High Estimate $0.51 $0.60 $2.03 $2.03
Low Estimate $0.46 $0.60 $2.01 $1.78
Prior Year $1.03 $0.95 $4.26 $2.02
Growth Rate (Year over Year) -53.40% -36.84% -52.58% -5.61%
Chart Benchmark
Average Frequency Timeframe
Indicator Chart Scale  
Symbol Comparison Bollinger Bands

Cempra Is Ready to Run Real Money Pro($)

Given predictable upcoming catalysts and a large addressable market, this small-cap biotech is a buy.
Immediate public backlash on social media could end up being a more costly verdict for drugmakers' pricing powers.
Pfizer's second acquisition this week could add risk. Some retailers attract portfolio managers.
There's a price to pay for low expectations.
Barring a strong rally over $31 that has follow-through, we look for AZN to slowly erode.

Bret Jensen Reporting for Duty Real Money Pro($)

Good morning! Bret Jensen here!
Inovio Pharmaceuticals and Eagle Pharmaceuticals both boast solid pipelines and sound balance sheets.
Small biotech has plenty of cash and a very valuable drug.
Small biotech has plenty of cash and a very valuable drug.
CEO Read says the Viagra maker retains the means to pursue 'attractive business development' opportunities as he tears up the six-month-old deal with the maker of Botox.

Columnist Conversations

we saw decent numbers from mr softie, our calls up nicely. We'll roll up. SOLD MSFT DEC 55 CAL...
we have a stellar winner here, will sell it and move on. SECOND this week! SOLD NFLX NOV 120 CALL AT ...
UK-based Manpower Group (MAN) reported better than expected Q3 earnings, at $1.87 versus a $1.72 estimate. ...
Join me for a very exclusive webinar with the amazing Mark Mahaney, from RBC Capital Markets.  Mark is on...


News Breaks

Powered by


Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.